Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Compare

2,220 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AXSM Analyst Ratings

Strong Buy

16 Buy

0 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Axsome

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AXSM Stock 12 Month Forecast

Average Price Target

$169.71

▲(39.27% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $169.71 with a high forecast of $200.00 and a low forecast of $144.00. The average price target represents a 39.27% change from the last price of $121.86.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"83":"$83","142":"$142","201":"$201","112.5":"$112.5","171.5":"$171.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":169.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$169.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":144,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$144.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[83,112.5,142,171.5,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.02,110.47999999999999,117.94,125.39999999999999,132.85999999999999,140.32,147.78,155.24,162.7,170.16,177.62,185.07999999999998,192.54,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.02,108.14999999999999,113.28,118.41,123.53999999999999,128.67000000000002,133.8,138.93,144.06,149.19,154.32,159.45,164.58,{"y":169.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.02,106.17230769230768,109.32461538461538,112.47692307692307,115.62923076923076,118.78153846153846,121.93384615384615,125.08615384615385,128.23846153846154,131.39076923076922,134.5430769230769,137.69538461538463,140.8476923076923,{"y":144,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":86.01,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.86,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.84,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.54,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 81,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 77,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.97,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$200.00

Average Price Target$169.71

Lowest Price Target$144.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ram Selvaraju

H.C. Wainwright

$180

Buy

47.71%

Upside

Reiterated

08/22/25

Positive Outlook for Axsome Therapeutics Amidst SYMBRAVO's Market Expansion and Patent StrengthValuation and Risks. Our Buy rating and $180 price target are based on a discounted cash flow (DCF)-based analysis. We apply a 10% discount rate to all future cash flows along with a 28.1% effective tax rate and a ~16% sales and marketing offset rate. This yields a total firm value of ~$10.8B, or a price per share of $180 given ~60.4M fully diluted shares outstanding as of mid-2026.

Graig Suvannavejh

Mizuho Securities

$200

Buy

64.12%

Upside

Reiterated

08/21/25

Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Rocket Pharmaceuticals (RCKT)

Dex Genotek

TR | OpenAI - 4o

$114→$116

Hold

-4.81%

Downside

Reiterated

08/21/25

AI Generated ArticleAI Generated Article

Leonid Timashev

RBC Capital

$189

Buy

55.10%

Upside

Reiterated

08/20/25

RBC Capital Keeps Their Buy Rating on Axsome Therapeutics (AXSM)

Ami Fadia

Needham

$150

Buy

23.09%

Upside

Reiterated

08/11/25

Analysts' Top Healthcare Picks: EyePoint Pharmaceuticals (EYPT), Axsome Therapeutics (AXSM)We update our model for the quarter and reiterate our Buy rating.

Ashwani Verma

UBS

$151→$144

Buy

18.17%

Upside

Reiterated

08/06/25

UBS Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

Joon Lee

Truist Financial

―

Buy

―

Reiterated

08/05/25

Myles Minter

William Blair

―

Buy

―

Reiterated

08/04/25

Axsome Therapeutics: Strong Financial Performance and Strategic Advancements Reinforce Buy Rating

Marc Goodman

Leerink Partners

$150

Buy

23.09%

Upside

Reiterated

08/04/25

Axsome Therapeutics: Strong Sales Performance and Promising Growth Trajectory Reinforce Buy Recommendation

Jason Gerberry

Bank of America Securities

$173→$176

Buy

44.43%

Upside

Reiterated

08/04/25

Optimistic Outlook for Axsome Therapeutics: Strong Financial Performance and Growth Potential Justify Buy Rating

Sean Laaman

Morgan Stanley

$190→$191

Buy

56.74%

Upside

Reiterated

08/04/25

Axsome Therapeutics: Strong Sales Performance and Strategic Growth Initiatives Drive Buy Rating

Cerena Chen

Wells Fargo

$165

Buy

35.40%

Upside

Reiterated

08/04/25

Wells Fargo Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)

Joseph Thome

TD Cowen

$190

Buy

55.92%

Upside

Reiterated

08/04/25

Strong Growth Prospects and Strategic Advancements Propel Axsome Therapeutics to 'Buy' Rating

Matthew Hershenhorn

Oppenheimer

$183

Buy

50.17%

Upside

Reiterated

07/31/25

Oppenheimer Remains a Buy on Axsome Therapeutics (AXSM)

David Amsellem

Piper Sandler

$148

Buy

21.45%

Upside

Reiterated

07/29/25

Piper Sandler Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ram Selvaraju

H.C. Wainwright

$180

Buy

47.71%

Upside

Reiterated

08/22/25

Graig Suvannavejh

Mizuho Securities

$200

Buy

64.12%

Upside

Reiterated

08/21/25

Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Rocket Pharmaceuticals (RCKT)

Dex Genotek

TR | OpenAI - 4o

$114→$116

Hold

-4.81%

Downside

Reiterated

08/21/25

AI Generated ArticleAI Generated Article

Leonid Timashev

RBC Capital

$189

Buy

55.10%

Upside

Reiterated

08/20/25

RBC Capital Keeps Their Buy Rating on Axsome Therapeutics (AXSM)

Ami Fadia

Needham

$150

Buy

23.09%

Upside

Reiterated

08/11/25

Analysts' Top Healthcare Picks: EyePoint Pharmaceuticals (EYPT), Axsome Therapeutics (AXSM)We update our model for the quarter and reiterate our Buy rating.

Ashwani Verma

UBS

$151→$144

Buy

18.17%

Upside

Reiterated

08/06/25

UBS Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

Joon Lee

Truist Financial

―

Buy

―

Reiterated

08/05/25

Myles Minter

William Blair

―

Buy

―

Reiterated

08/04/25

Axsome Therapeutics: Strong Financial Performance and Strategic Advancements Reinforce Buy Rating

Marc Goodman

Leerink Partners

$150

Buy

23.09%

Upside

Reiterated

08/04/25

Axsome Therapeutics: Strong Sales Performance and Promising Growth Trajectory Reinforce Buy Recommendation

Jason Gerberry

Bank of America Securities

$173→$176

Buy

44.43%

Upside

Reiterated

08/04/25

Optimistic Outlook for Axsome Therapeutics: Strong Financial Performance and Growth Potential Justify Buy Rating

Sean Laaman

Morgan Stanley

$190→$191

Buy

56.74%

Upside

Reiterated

08/04/25

Axsome Therapeutics: Strong Sales Performance and Strategic Growth Initiatives Drive Buy Rating

Cerena Chen

Wells Fargo

$165

Buy

35.40%

Upside

Reiterated

08/04/25

Wells Fargo Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)

Joseph Thome

TD Cowen

$190

Buy

55.92%

Upside

Reiterated

08/04/25

Strong Growth Prospects and Strategic Advancements Propel Axsome Therapeutics to 'Buy' Rating

Matthew Hershenhorn

Oppenheimer

$183

Buy

50.17%

Upside

Reiterated

07/31/25

Oppenheimer Remains a Buy on Axsome Therapeutics (AXSM)

David Amsellem

Piper Sandler

$148

Buy

21.45%

Upside

Reiterated

07/29/25

Piper Sandler Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Axsome Therapeutics

1 Month

xxx

Success Rate

18/29 ratings generated profit

Average Return

+13.66%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.07% of your transactions generating a profit, with an average return of +13.66% per trade.

3 Months

xxx

Success Rate

17/24 ratings generated profit

Average Return

+13.20%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.83% of your transactions generating a profit, with an average return of +13.20% per trade.

1 Year

Leonid TimashevRBC Capital

Success Rate

18/19 ratings generated profit

Average Return

+26.56%

reiterated a buy rating 9 days ago

Copying Leonid Timashev's trades and holding each position for 1 Year would result in 94.74% of your transactions generating a profit, with an average return of +26.56% per trade.

2 Years

xxx

Success Rate

31/32 ratings generated profit

Average Return

+59.77%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 96.88% of your transactions generating a profit, with an average return of +59.77% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AXSM Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AXSM has received 57 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. AXSM average Analyst price target in the past 3 months is 169.71.

Each month's total comprises the sum of three months' worth of ratings.

AXSM Financial Forecast

AXSM Earnings Forecast

Next quarter’s earnings estimate for AXSM is -$0.83 with a range of -$1.14 to -$0.53. The previous quarter’s EPS was -$0.97. AXSM beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.19% of the time in the same period. In the last calendar year AXSM has Outperformed its overall industry.

AXSM Sales Forecast

Next quarter’s sales forecast for AXSM is $163.52M with a range of $153.50M to $172.60M. The previous quarter’s sales results were $150.04M. AXSM beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.91% of the time in the same period. In the last calendar year AXSM has Outperformed its overall industry.

AXSM Stock Forecast FAQ

What is AXSM’s average 12-month price target, according to analysts?

Based on analyst ratings, Axsome Therapeutics Inc.’s 12-month average price target is 169.71.

What is AXSM’s upside potential, based on the analysts’ average price target?

Axsome Therapeutics Inc. has 39.27% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AXSM a Buy, Sell or Hold?

Axsome Therapeutics Inc. has a consensus rating of Strong Buy which is based on 16 buy ratings, 0 hold ratings and 0 sell ratings.

What is Axsome Therapeutics Inc.’s price target?

The average price target for Axsome Therapeutics Inc. is 169.71. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $200.00 ,the lowest forecast is $144.00. The average price target represents 39.27% Increase from the current price of $121.86.

What do analysts say about Axsome Therapeutics Inc.?

Axsome Therapeutics Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of AXSM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

AXSM Analyst Ratings

AXSM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Axsome Therapeutics

AXSM Analyst Recommendation Trends

AXSM Financial Forecast

AXSM Earnings Forecast

AXSM Sales Forecast

AXSM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts